T-DM1 demonstrated a favorable anti-tumor effect against HER2 overexpressing breast cancer as an adjuvant, first- and second-line therapy in phase III clinical trials but, less or no effect in low HER2 expression. Here, ERBB2 is linked to breast carcinoma.